meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
versus all
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab plus platin plus 5FU
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab based treatment
pembrolizumab alone
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
Comparator:
vs cetuximab plus platin plus 5FU;
Risk of bias:
low;
some concerns;
high;
NA;